PFIZER INC Impairment of Long-Lived Assets Held-for-use
PFIZER INC (PFE) reported Impairment of Long-Lived Assets Held-for-use of $210.00 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2013-02-28
- PFIZER INC impairment of long-lived assets held-for-use for the quarter ending 2012-12-31 was -$10.00M, a 110.10% decline year-over-year.
- PFIZER INC impairment of long-lived assets held-for-use for the quarter ending 2012-09-30 was -$7.00M, a 107.07% decline year-over-year.
- PFIZER INC impairment of long-lived assets held-for-use for the quarter ending 2012-07-01 was $9.00M, a 72.73% decline year-over-year.
- PFIZER INC impairment of long-lived assets held-for-use for the quarter ending 2012-04-01 was $218.00M, a 772.00% increase year-over-year.
- PFIZER INC impairment of long-lived assets held-for-use for fiscal 2012 was $210.00M, a 17.97% decline from fiscal 2011.
- PFIZER INC impairment of long-lived assets held-for-use for fiscal 2011 was $256.00M, a 70.57% decline from fiscal 2010.
- PFIZER INC impairment of long-lived assets held-for-use for fiscal 2010 was $870.00M, a 447.17% increase from fiscal 2009.
- PFIZER INC impairment of long-lived assets held-for-use for fiscal 2009 was $159.00M, a 70.72% decline from fiscal 2008.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2012-12-31 | -$10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | -$17.00M derived: sum of 2 quarters · filed 2013-02-28 | -$8.00M derived: sum of 3 quarters · filed 2013-02-28 | $210.00M 10-K · filed 2013-02-28 |
| 2012-09-30 | -$7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $2.00M derived: sum of 2 quarters · filed 2012-11-09 | $220.00M 10-Q · filed 2012-11-09 | $319.00M derived: sum of 4 quarters · filed 2012-11-09 |
| 2012-07-01 | $9.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $227.00M 10-Q · filed 2012-08-09 | $326.00M derived: sum of 3 quarters · filed 2012-08-09 | $425.00M derived: sum of 4 quarters · filed 2012-08-09 |
| 2012-04-01 | $218.00M 10-Q · filed 2012-05-10 | $317.00M derived: sum of 2 quarters · filed 2012-05-10 | $416.00M derived: sum of 3 quarters · filed 2012-05-10 | $449.00M derived: sum of 4 quarters · filed 2012-05-10 |
| 2011-12-31 | $99.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $198.00M derived: sum of 2 quarters · filed 2012-02-28 | $231.00M derived: sum of 3 quarters · filed 2012-02-28 | $256.00M 10-K · filed 2012-02-28 |
| 2011-10-02 | $99.00M 10-Q · filed 2011-11-10 | $132.00M derived: sum of 2 quarters · filed 2011-11-10 | $157.00M 10-Q · filed 2011-11-10 | $350.00M derived: sum of 4 quarters · filed 2012-05-10 |
| 2011-07-03 | $33.00M 10-Q · filed 2011-08-11 | $58.00M 10-Q · filed 2011-08-11 | $251.00M derived: sum of 3 quarters · filed 2012-05-10 | $425.00M derived: sum of 4 quarters · filed 2012-05-10 |
| 2011-04-03 | $25.00M 10-Q · filed 2012-05-10 | $218.00M derived: sum of 2 quarters · filed 2012-05-10 | $392.00M derived: sum of 3 quarters · filed 2012-05-10 | $889.00M derived: sum of 4 quarters · filed 2012-05-10 |
| 2010-12-31 | $193.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $367.00M derived: sum of 2 quarters · filed 2012-02-28 | $864.00M derived: sum of 3 quarters · filed 2012-02-28 | $870.00M 10-K · filed 2012-02-28 |
| 2010-10-03 | $174.00M 10-Q · filed 2011-11-10 | $671.00M derived: sum of 2 quarters · filed 2011-11-10 | $677.00M 10-Q · filed 2011-11-10 | $728.00M derived: sum of 4 quarters · filed 2012-02-28 |
| 2010-07-04 | $497.00M 10-Q · filed 2011-08-11 | $503.00M 10-Q · filed 2011-08-11 | $554.00M derived: sum of 3 quarters · filed 2012-02-28 | $571.00M derived: sum of 4 quarters · filed 2012-02-28 |
| 2010-04-04 | $6.00M 10-Q · filed 2011-05-12 | $57.00M derived: sum of 2 quarters · filed 2012-02-28 | $74.00M derived: sum of 3 quarters · filed 2012-02-28 | |
| 2009-12-31 | $51.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $68.00M derived: sum of 2 quarters · filed 2012-02-28 | $159.00M 10-K · filed 2012-02-28 | |
| 2009-09-27 | $17.00M 10-Q · filed 2010-11-12 | $108.00M 10-Q · filed 2010-11-12 | ||
| 2008-12-31 | $543.00M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |